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1.1 Supplementary Figure 1 
Supplementary Fig. 1. EMV subpopulations isolated from the three cancer cell lines are 
exosomes and MVs. This is shown in Figures A-D as following by: A-B) electron microscopy, with 
exosomes (A) corresponding to vesicles in the < 100 nm NTA peak, and MVs (B) corresponding to 
the 100-500 nm NTA peak (scale bars are indicated as 50 nm for A and 200 nm for B respectively); C) 
PS exposition, which is enriched in the MV population (11,000g fraction; 100-500 nm peak on NTA); 
D) Western blotting for CD63 expression (exosome marker), showing increased expression of CD63 






























1.2 Supplementary Figure 2 
Supplementary Fig. 2. HEPG2 and MDA-MB-231 cell viability following longer term (24 h) CBD 
treatment. Longer term (24 h) treatment effects of CBD on cancer cell viability was assessed for 
HEPG-2 and MDA-MB-231, showing dose-depended reduction in cell viability compared to control 
DMSO treated cells. In HEPG2 cells, 1 µM CBD resulted in a 38.8% decrease in cell viability, and 5 
µM CBD in a 47.2% decrease in cell viability compared to DMSO treated control cells. In MDA-MB-
231 cells, 1 µM CBD resulted in a 12.9% decrease in cell viability and 5 µM CBD in a 35.8% decrease 
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1.3 Supplementary Figure 3 
Supplementary Fig. 3. EMV profiles of PC3, HEPG2 and MDA-MB-231 cancer cells. A) A range 
in the total amount of EMVs (0-900 nm) released was observed, as well as differences in the 
proportions of exosomes (<100 nm) and microvesicles (MVs; 100-900 nm) released from untreated 
cells (absence of CBD, Cl-amidine or DMSO). While PC3 cells released the highest amount of EMVs 
and similar proportions of exosomes and MVs, both HEPG2 and MDA-MB-231 released a higher 
proportion of MVs versus exosomes. B) In addition, a range in the proportional release of the two MV 
subsets at 100-200 nm and 201-500 nm are observed between the three cell lines, particularly regarding 
the 201-500 nm subset which is proportionally highest in HEPG2 compared to PC3 and MDA-MB-
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1.4 Supplementary Figure 4 
Supplementary Fig. 3.  Nanosight Tracking Analysis (NTA) of EMVs released from HEPG2 
cancer cells in the presence of CBD, Cl-amidine and combinatory application of CBD and Cl-
amidine.  Representative plots from Nanosight tracking analysis show the concentration of total 
vesicles (0–900 nm in diameter) released from HEPG2 cancer cells. Vesicles outside this size range 
were excluded to avoid including larger vesicles such as MV aggregates or apoptotic bodies. The peak 
at 201-401 nm (as indicated by block arrows) observed in non-treated control cells (A) is notably 
reduced in CBD treated HEPG2 cells (B). This is also observed in combinatory treatment using Cl-
amidine and CBD combined (D), while in the Cl-amidine treated cells the peak is present (C). The 
experiment was repeated three times in total with 5 readings performed for each sample for an average 
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1.5 Supplementary Figure 5  
Supplementary Fig. 5. ROS levels increase following 1 h CBD treatment in MDA-MB-231 cancer 
cells. MDA-MB-231 cells were treated with CBD for 1 h. ROS levels were measured after incubation 
using a 2′,7′-Dichlorofluorescin diacetate (DCFDA) assay according to the manufacturer’s instructions 
(Abcam, UK). The amount of ROS was detected on a fluorescent plate read (FLUOstar Omega, BMG 
Labtech, UK) with an excitation of 495 nm and emission of 529 nm. The optical density was 
background subtracted and measured as a percentage of untreated cells after being normalized to cell 
count. This was carried out three times for experimental replication, with technical replicates of 5 wells 
per plate per treatment. Cancer cells showed a significant increase in ROS levels with increasing CBD; 
1 µM CBD (1.30 ± 0.078 A.U.) and 5 µM CBD (1.84 ± 0.149 A.U.). Data shown is repeated 3 times 
with 5 replicates per plate and is normalised to cell count. Dashed line represents untreated levels. Data 
is represented as mean ± SEM; **p<0.01, ***p<0.001 versus control treated cells. 
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